Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with a confirmed brain or central nervous system (CNS) tumour that tests positive for a protein called GD2, or has a specific genetic change called H3K27 alteration — this includes newly diagnosed tumours, as well as tumours that have come back, stopped responding to treatment, or are getting worse. Tumour types may include certain high-grade brain tumours (DMG/HGG), medulloblastoma, AT/RT, ependymoma, and related tumours (confirm specific tumour type eligibility with trial site)
• People whose tumour measures less than 5 cm at its largest point when joining the trial (tumours between 5 and 5.5 cm may still be considered if the tumour was surgically reduced in size)
• People whose tumour showed some growth after radiation therapy may still be considered, depending on the degree of growth and follow-up scan results (confirm with trial site)
• People whose tumour can be measured in at least two directions on an MRI scan
• People aged between 12 months and 25 years
• People with a functional ability score of at least 50 out of 100 on standard medical scales (or at least 60 for one specific group in the trial), reflecting the ability to carry out daily activities
• People who have a central line (a type of intravenous access) and a specific device called an Ommaya reservoir or VP shunt already in place, or planned to be placed, for treatment delivery
• People who completed standard radiation therapy at least 4 weeks before starting the trial treatment (and, if a drug called bevacizumab was used, that treatment must also have been finished at least 4 weeks prior)
• People whose neurological symptoms (such as movement, speech, or thinking) have been stable for at least 7 days before joining
• People who are on a stable or reducing dose of steroid medication, with a daily dose of dexamethasone no higher than 0.1 mg per kg of body weight over the 7 days before treatment
• People whose blood counts, liver function, and kidney function meet specific laboratory thresholds set by the trial (confirm exact values with trial site)

Who may not be able to join:

• People who are pregnant or breastfeeding
• People who received another type of immunotherapy treatment within the 42 days before the trial treatment would begin
• People who received certain blood cell-boosting medications (colony-stimulating factors) within 14 days before a specific part of the trial treatment called lymphodepletion
• People who are currently receiving any other cancer treatment, or have not waited long enough after finishing prior cancer treatment (the required gap depends on the specific treatment used)
• People for whom the trial investigators consider the experimental treatment to not be in their best interest due to other health risks

Important: Always verify eligibility with the trial site directly before applying.